AR040969A1 - Composiciones farmaceuticas de farmacos semiordenados y polimeros - Google Patents
Composiciones farmaceuticas de farmacos semiordenados y polimerosInfo
- Publication number
- AR040969A1 AR040969A1 ARP030102902A ARP030102902A AR040969A1 AR 040969 A1 AR040969 A1 AR 040969A1 AR P030102902 A ARP030102902 A AR P030102902A AR P030102902 A ARP030102902 A AR P030102902A AR 040969 A1 AR040969 A1 AR 040969A1
- Authority
- AR
- Argentina
- Prior art keywords
- drug
- composition
- control composition
- low solubility
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una composición caracterizada porque comprende: a) un sólido que comprende un fármaco de baja solubilidad y un polímero potenciador de la concentración; b) estando presente el citado polímero potenciador de la concentración en la citada composición en una cantidad suficiente para que la citada composición proporcione una concentración potenciada del citado fármaco de baja solubilidad en un entorno de uso respecto a una primera composición de control constituida esencialmente por una mezcla de una cantidad equivalente del citado fármaco en forma cristalina y una cantidad equivalente del citado polímero potenciador de la concentración; y c) en la que al menos una porción del citado fármaco está presente en regiones ricas en fármaco, y las citadas regiones ricas en fármaco están intercaladas a lo largo de regiones pobres en fármaco ricas en polímero, y en la que al menos un 20% en peso del citado fármaco de baja solubilidad está en un estado semiordenado. Reivindicación 3: La composición de la reivindicación 1, caracterizado porque el citado fármaco en el citado estado semiordenado exhibe al menos uno de: a) un patrón de difracción de rayos X en polvo que es diferente del patrón e rayos X en polvo de la citada primera composición de control, en el que al menos un pico presente en el citado patrón de difracción de la citada primera composición de control no está presente en el citado patrón de difracción del citado fármaco en la citada composición; b) un patrón de difracción de rayos X en polvo que tiene al menos un pico que tiene una anchura total a mitad de altura de al menos 1,1 veces la de un pico equivalente exhibido por el citado fármaco en la citada primera composición de control; c) una temperatura de transición vítrea que es diferente de la temperatura de transición vítrea de la citada segunda composición e control; estando constituida esencialmente la citada segunda composición de control por una dispersión sólida amorfa de una cantidad equivalente del citado fármaco y una cantidad equivalente del citado polímero potenciador de la concentración, siendo el citado fármaco en la citada segunda composición de control al menos un 90 % en peso amorfo; y d) un inicio o máximo de la endotermia de fusión que está a una temperatura inferior al inicio o máximo de la endotermia de la mezcla fundida del citado fármaco en la citada primera< composición de control. Reivindicación 9: Un proceso para formar una composición de control caracterizado porque comprende: a) formar una dispersión amorfa que comprende un fármaco de baja solubilidad y un polímero potenciador de la concentración; b) tratar la citada dispersión amorfa para aumentar la movilidad del citado fármaco en la citada dispersión amorfa mediante al menos uno de (1) calentar la citada dispersión y (2) exponer la citada dispersión a un agente potenciador de la movilidad; y c) convertir al menos un 20 % en peso del citado fármaco de baja solubilidad a un estado semiordenado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40308702P | 2002-08-12 | 2002-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR040969A1 true AR040969A1 (es) | 2005-04-27 |
Family
ID=31715934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030102902A AR040969A1 (es) | 2002-08-12 | 2003-08-11 | Composiciones farmaceuticas de farmacos semiordenados y polimeros |
Country Status (24)
Country | Link |
---|---|
US (2) | US8257739B2 (es) |
EP (2) | EP2111856A3 (es) |
JP (1) | JP2006500349A (es) |
CN (1) | CN1681479A (es) |
AR (1) | AR040969A1 (es) |
AT (1) | ATE442130T1 (es) |
AU (1) | AU2003249474A1 (es) |
BR (1) | BR0313428A (es) |
CA (1) | CA2496441C (es) |
DE (1) | DE60329188D1 (es) |
ES (1) | ES2333318T3 (es) |
GT (1) | GT200300170A (es) |
IL (1) | IL166411A0 (es) |
MX (1) | MXPA05000977A (es) |
NO (1) | NO20050419L (es) |
PA (1) | PA8579801A1 (es) |
PE (1) | PE20040865A1 (es) |
PL (1) | PL375345A1 (es) |
PT (1) | PT1530457E (es) |
RU (1) | RU2005103625A (es) |
TW (1) | TW200406224A (es) |
UY (1) | UY27929A1 (es) |
WO (1) | WO2004014342A1 (es) |
ZA (1) | ZA200500470B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2359945C (en) * | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
EP1404300B1 (en) * | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
CA2577852A1 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
US9265731B2 (en) | 2005-01-28 | 2016-02-23 | Bend Research, Inc. | Drying of drug-containing particles |
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
EP2043610B1 (en) | 2006-07-21 | 2015-07-01 | Bend Research, Inc. | Drying of drug-containing particles |
EP2140883B1 (en) * | 2007-04-20 | 2012-10-31 | Daido Chemical Corporation | Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion |
CN102686600A (zh) | 2009-02-05 | 2012-09-19 | 托凯药业股份有限公司 | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
MX2013010306A (es) | 2011-03-08 | 2013-12-09 | Zalicus Pharmaceuticals Ltd | Formulaciones de dispersion solida y metodos de uso de las mismas. |
TW201311240A (zh) * | 2011-07-21 | 2013-03-16 | 必治妥美雅史谷比公司 | 非晶形哌啶基化合物之生物可利用組合物 |
BR112015015846A2 (pt) | 2013-03-07 | 2017-07-11 | Dow Global Technologies Llc | éter de celulose esterificado, composição, dispersão sólida, forma de dosagem, invólucro de cápsula e processo para produzir um éter de celulose esterificado |
KR102194967B1 (ko) | 2013-03-07 | 2020-12-24 | 다우 글로벌 테크놀로지스 엘엘씨 | 초고분자량의 신규한 에스테르화된 셀룰로스 에테르 |
JP6321688B2 (ja) | 2013-03-07 | 2018-05-09 | ダウ グローバル テクノロジーズ エルエルシー | 低粘度の新規エステル化セルロースエーテル |
EP2968370A4 (en) | 2013-03-14 | 2016-09-21 | Univ Maryland | AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF |
EP2832723B1 (en) * | 2013-07-29 | 2017-02-15 | Zentiva, a.s. | Stabilised amorphous forms of Saxagliptin |
JP2016528252A (ja) | 2013-08-12 | 2016-09-15 | トーカイ ファーマシューティカルズ, インコーポレイテッド | アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー |
CA2962719A1 (en) | 2014-10-31 | 2016-05-06 | Bend Research Inc. | Process for forming active domains dispersed in a matrix |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
JPS6314724A (ja) * | 1986-07-08 | 1988-01-21 | Tooa Eiyoo Kk | プラゾシン製剤 |
JPH02149518A (ja) * | 1988-11-30 | 1990-06-08 | Nikken Chem Co Ltd | 経口投与用薬剤 |
DK546289D0 (da) | 1989-11-02 | 1989-11-02 | Danochemo As | Carotenoidpulvere |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO1992018106A1 (en) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Method of manufacturing solid dispersion |
DE4140184C2 (de) | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Akutform für ein Flurbiprofen enthaltendes Arzneimittel |
DE4140185C2 (de) | 1991-12-05 | 1996-02-01 | Alfatec Pharma Gmbh | Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung |
US5876754A (en) | 1992-01-17 | 1999-03-02 | Alfatec-Pharma Gmbh | Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
US5811547A (en) | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
DE4316537A1 (de) | 1993-05-18 | 1994-11-24 | Basf Ag | Zubereitungen in Form fester Lösungen |
JP3345761B2 (ja) * | 1993-06-16 | 2002-11-18 | 日本特殊陶業株式会社 | ヒーター付スパークプラグ及びその製造方法 |
DE4327063A1 (de) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
DE4329446A1 (de) | 1993-09-01 | 1995-03-02 | Basf Ag | Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen |
DE19509807A1 (de) | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5685331A (en) | 1994-12-20 | 1997-11-11 | Ac & R Components, Inc. | Oil level regulator |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5716642A (en) | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
DE19509805A1 (de) | 1995-03-21 | 1996-09-26 | Basf Ag | Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica |
DE19509806A1 (de) | 1995-03-21 | 1996-09-26 | Basf Ag | Lagerstabile Arzneiformen |
WO1997013503A1 (en) | 1995-10-13 | 1997-04-17 | The Penn State Research Foundation | Synthesis of drug nanoparticles by spray drying |
US5874029A (en) | 1996-10-09 | 1999-02-23 | The University Of Kansas | Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent |
US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
JPH09309828A (ja) * | 1996-03-18 | 1997-12-02 | Eisai Co Ltd | 溶解を改善した薬剤組成物 |
IL117773A (en) | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
JPH107558A (ja) * | 1996-06-19 | 1998-01-13 | Eisai Co Ltd | 溶解性改善製剤 |
DE19629753A1 (de) | 1996-07-23 | 1998-01-29 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
DE19637517A1 (de) | 1996-09-13 | 1998-03-19 | Basf Ag | Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
CN1248968A (zh) | 1997-02-26 | 2000-03-29 | 辉瑞大药厂 | 杂芳基-己酸酰胺衍生物、其制备方法及其作为MIP-1α与其CCRI受体结合的选择性抑制剂的用途 |
US6126451A (en) | 1997-06-02 | 2000-10-03 | Compaq Computer Corporation | SCSI connector |
ES2287971T3 (es) * | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
HN1998000115A (es) | 1997-08-21 | 1999-06-02 | Warner Lambert Co | Formas de dosificación farmacéuticas sólidas |
AU752407B2 (en) | 1998-02-05 | 2002-09-19 | Pfizer Products Inc. | Novel dihydroxyhexanoic acid derivatives |
US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
ES2310164T3 (es) * | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | Dispositivo de liberacion controlada por la matriz. |
ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
MXPA02006324A (es) * | 1999-12-23 | 2002-12-13 | Pfizer Prod Inc | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco. |
UY26615A1 (es) * | 2000-03-16 | 2001-10-25 | Pfizer Prod Inc | Inhibidor de la glucogeno fosforilasa. |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
EP1401503B1 (en) | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
EP1401399A2 (en) * | 2001-06-22 | 2004-03-31 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
CA2461890C (en) | 2001-09-28 | 2010-12-14 | Solubest Ltd. | Water soluble nanoparticles of hydrophilic and hydrophobic active materials |
US6848693B2 (en) * | 2001-11-20 | 2005-02-01 | Actuant Corporation | Pseudo four-leg vehicle leveling system with independent leg lock-out |
BR0307333A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização |
CA2547404A1 (en) | 2003-12-09 | 2005-06-23 | Pfizer Inc. | Compositions comprising an hiv protease inhibitor |
-
2003
- 2003-07-31 CA CA2496441A patent/CA2496441C/en not_active Expired - Fee Related
- 2003-07-31 BR BR0313428-8A patent/BR0313428A/pt not_active Withdrawn
- 2003-07-31 AU AU2003249474A patent/AU2003249474A1/en not_active Abandoned
- 2003-07-31 MX MXPA05000977A patent/MXPA05000977A/es unknown
- 2003-07-31 JP JP2004527196A patent/JP2006500349A/ja active Pending
- 2003-07-31 EP EP09007816.3A patent/EP2111856A3/en not_active Withdrawn
- 2003-07-31 AT AT03784384T patent/ATE442130T1/de not_active IP Right Cessation
- 2003-07-31 PL PL03375345A patent/PL375345A1/xx not_active Application Discontinuation
- 2003-07-31 RU RU2005103625/15A patent/RU2005103625A/ru not_active Application Discontinuation
- 2003-07-31 PT PT03784384T patent/PT1530457E/pt unknown
- 2003-07-31 DE DE60329188T patent/DE60329188D1/de not_active Expired - Lifetime
- 2003-07-31 WO PCT/IB2003/003465 patent/WO2004014342A1/en active Application Filing
- 2003-07-31 EP EP03784384A patent/EP1530457B1/en not_active Revoked
- 2003-07-31 CN CNA038213486A patent/CN1681479A/zh active Pending
- 2003-07-31 ES ES03784384T patent/ES2333318T3/es not_active Expired - Lifetime
- 2003-08-05 US US10/636,834 patent/US8257739B2/en active Active
- 2003-08-05 UY UY27929A patent/UY27929A1/es not_active Application Discontinuation
- 2003-08-06 GT GT200300170A patent/GT200300170A/es unknown
- 2003-08-06 PA PA20038579801A patent/PA8579801A1/es unknown
- 2003-08-08 PE PE2003000793A patent/PE20040865A1/es not_active Application Discontinuation
- 2003-08-11 TW TW092121979A patent/TW200406224A/zh unknown
- 2003-08-11 AR ARP030102902A patent/AR040969A1/es not_active Application Discontinuation
-
2005
- 2005-01-18 ZA ZA200500470A patent/ZA200500470B/xx unknown
- 2005-01-20 IL IL16641105A patent/IL166411A0/xx unknown
- 2005-01-25 NO NO20050419A patent/NO20050419L/no not_active Application Discontinuation
-
2012
- 2012-08-23 US US13/593,263 patent/US8491933B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2111856A3 (en) | 2014-09-10 |
RU2005103625A (ru) | 2005-08-20 |
MXPA05000977A (es) | 2005-05-16 |
IL166411A0 (en) | 2006-01-15 |
EP1530457A1 (en) | 2005-05-18 |
ZA200500470B (en) | 2006-07-26 |
NO20050419L (no) | 2005-04-04 |
US8257739B2 (en) | 2012-09-04 |
TW200406224A (en) | 2004-05-01 |
PL375345A1 (en) | 2005-11-28 |
PA8579801A1 (es) | 2004-02-16 |
CA2496441A1 (en) | 2004-02-19 |
US20120322805A1 (en) | 2012-12-20 |
US8491933B2 (en) | 2013-07-23 |
CN1681479A (zh) | 2005-10-12 |
BR0313428A (pt) | 2005-06-28 |
DE60329188D1 (de) | 2009-10-22 |
PT1530457E (pt) | 2009-11-06 |
EP1530457B1 (en) | 2009-09-09 |
AU2003249474A1 (en) | 2004-02-25 |
GT200300170A (es) | 2004-05-12 |
UY27929A1 (es) | 2004-03-31 |
PE20040865A1 (es) | 2004-11-25 |
CA2496441C (en) | 2010-03-16 |
EP2111856A2 (en) | 2009-10-28 |
ATE442130T1 (de) | 2009-09-15 |
US20040156905A1 (en) | 2004-08-12 |
WO2004014342A1 (en) | 2004-02-19 |
JP2006500349A (ja) | 2006-01-05 |
ES2333318T3 (es) | 2010-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR040969A1 (es) | Composiciones farmaceuticas de farmacos semiordenados y polimeros | |
GT200100183A (es) | Derivados de quinolina y quinazolina. | |
CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
GT200100160A (es) | Derivados 4-fenil-piridina. | |
CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
DOP2002000438A (es) | Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
AR033367A1 (es) | Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos | |
BRPI0510515A (pt) | compostos de morfolina | |
BR0315008A (pt) | Compostos neurologicamente ativos | |
SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
UY27891A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para la preparación de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos. | |
BRPI0713565B8 (pt) | processo para fabricação de uma forma de dosagem oral sólida | |
DE60330181D1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
DK1235826T3 (da) | Quinuclidinacrylamider | |
SV1999000048A (es) | Uso de dihidropiriminas como medicamento y nuevas sustancias ref. lea 32 791-sv | |
PA8456901A1 (es) | 2-aminopiridinas que contienen sustituyentes de anillos condensados | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
AR036813A1 (es) | Composiciones farmaceuticas | |
PA8556901A1 (es) | Nuevos derivados de piperazina | |
BR0115584A (pt) | Esterilização de produtos farmacêuticos | |
ATE443541T1 (de) | Zusammensetzungen mit strontium und vitamin d und ihre verwendungen | |
AR029289A1 (es) | Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo | |
AR013001A1 (es) | Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina. | |
ECSP066484A (es) | Compuestos y metodos para el tratamiento de dislipidemia | |
BRPI0315644B8 (pt) | compostos de piperazinil e diazapanil benzamidas e benzotioamidas, suas composições e respectivos usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |